N-(1-Oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-D-valine

CAS: 137862-87-4

Ref. 3D-IO22697

Informação sobre produto

• Nome: N-(1-Oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-D-valine
• Sinónimos: Valsartan related compound Aent-ValsartanD-Valsartan, 3-Methyl-2-[Pentanoyl-[[4-[2-(2H-Tetrazol-5-Yl)Phenyl]Phenyl]Methyl]Amino]-Butanoic Acid, N-pentanoyl-N-{[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}valine, N-pentanoyl-N-{[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine, N-pentanoyl-N-{[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-D-valine, D-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, Valsartan(Diovan), N-(1-Oxopentyl)-N-((2'-(1H-Tetrazol-5-Yl)(1,1'-Biphenyl)-3-Yl)Methyl)-L-Valine
• CAS: 137862-87-4

Descrição

N-(1-Oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-D-valine is a potent and selective inhibitor of the enzyme lipase. It prevents the hydrolysis of triglycerides by competitively binding to the active site of lipase. This inhibition leads to an increase in serum levels of triglycerides, which are associated with cardiometabolic risk factors. Novartis developed this drug as an alternative to sacubitril/valsartan, which is used for the treatment of heart failure. The pharmacokinetics and pharmacodynamics of this drug are similar to those of sacubitril/valsartan. N-(1-Oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-D-

• Marca: Biosynth

Propriedades químicas

• Peso molecular: 435.52 g/mol
• Fórmula: C₂₄H₂₉N₅O₃
• Pureza: Min. 95%
• Cor/forma: White To Off-White Solid
• InChI: InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m1/s1
• Chave InChI: InChIKey=ACWBQPMHZXGDFX-JOCHJYFZSA-N
• SMILES: CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@@H](C(=O)O)C(C)C